• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Lowered Guidance Won’t Stop Covance

Lowered Guidance Won’t Stop Covance

January 5, 2009
CenterWatch Staff

Global contract research organization (CRO) Covance ended the year with a flurry, lowering its 2008 guidance, purchasing an equity stake in a proteomics biomarker services provider and adding four executive positions.

The Princeton, N.J.-based company lowered its full-year 2008 guidance in late December, after experiencing a slower-than-expected fourth quarter. The CRO expects its full-year earnings per share to be $3.02 with “low double-digit” revenue growth, versus its previous full-year estimates of $3.18 per diluted share with 20% annual growth.

“During the fourth quarter, demand for our toxicology and clinical pharmacology services are below our expectations due to a combination of lower new project initiatives and a further increase in project delays from Q4 into 2009,” said Covance chairman and CEO Joe Herring in an investor conference call last month.

Covance expects full-year 2009 revenue growth to be in the range of 5% to 10% compared with 2008 and earnings per share to be in the range of $3.00 to $3.20.

Herring told investors that the company will take a more conservative approach to its financial projections for 2009, as well as take steps to reduce expenses.

Covance continued with its end-of-year growth plans, however, with the purchase of a minority equity stake in Caprion Proteomics.

Under the terms of the agreement, Covance will serve as the exclusive CRO distributor of Caprion’s biomarker services, and Caprion will be Covance’s exclusive proteomic discovery provider.

Covance hopes the partnership will enhance the CRO’s biomarker services business— a high-growth market.

“We are very pleased to be adding Caprion’s solid scientific capabilities and leading biomarker technology platform to Covance’s line up,” said Covance’s corporate senior vice president and president of Covance Central Laboratory Services Deborah Tanner in a company release. “We expect that our clients will have a keen interest in this additional capability.”

To strengthen its biomarker business, Covance plans to establish a Biomarker Center of Excellence at its Greenfield, Ind., campus. The company acquired the 450-acre early drug development campus last August as part of a groundbreaking $1.6-billion deal with Eli Lilly.

Newly hired vice president of biomarkers Thomas Turi, Ph.D., will run Covance’s biomarker team and the planned Center of Excellence. Turi served as the senior director of translational biomarkers and mechanistic biology for Pfizer before joining Covance.

The company also added three new senior executive positions to its periapproval services team in December. Glynis Neagle, M.D., (formerly Covance’s senior director for clinical development) is the new vice president for medical affairs. He will oversee medical affairs, epidemiology and product safety. Robert Bader, the former senior director for global pharmacovigilance and epidemiology at Cephalon, will lead phase IIIb and IV pharmacovigilance programs as director for product safety services; and Thomas Noto will oversee regulatory affairs as the vice president for regulatory affairs.

Upcoming Events

  • 15Apr

    Five Telltale Signs You’re Ready for an Electronic TMF System

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Clinical-Trial-Brainstorming

    FDA, Industry Tackle Problem of Including Older Adults in Trials

  • ClinicalTrialNetwork-360x240.png

    National Community-Based Research Network Would Improve Reach of Trials

  • Bottleneck-360x240.png

    Sites Face Trials Bottleneck After Pandemic, But Also Opportunities

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Genetic Research and IBC Oversight Requirements

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing